Breadcrumb Home Studies Studies Search Filter Research Area All Study Status AllClosed to AccrualClosed to Follow UpConcludedEnrollingIn DevelopmentParticipants Off Study and Primary Analysis CompletedPending Sort Study Number AscStudy Number Desc Submit Search Showing 32 studies. IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection DAIDS Number 20734 Research Area Treatment Study Status Concluded IMPAACT 2000: A Phase I Study of the Safety and Immunogenicity of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID delta M2-2 in RSV-Seronegative Infants and Children DAIDS Number 12016 Research Area Complications & Comorbidities Study Status Concluded P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure and Immunotherapy Study Status Enrolling P1114: Safety and Immunogenicity of an RSV Vaccine cps2 DAIDS Number 11948 Research Area Complications & Comorbidities Study Status Concluded P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) Given in Combination with an Individualized Rifampin-Resistant Tuberculosis (RR-TB) Therapy in Infants, Children and Adolescents with RR-TB Disease, Living with or without HIV DAIDS Number 11884 Research Area Tuberculosis Study Status Closed to Accrual P1104s: Longitudinal Developmental and Neuropsychological Assessments of HIV-Infected Participants of P1060 and HIV-Uninfected Controls DAIDS Number 11878 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed P1100: AERAS 402 DAIDS Number 11801 Research Area Tuberculosis Study Status Concluded P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics P1084s: Maternal Infant TDF Toxicity Safety DAIDS Number 10790 Research Area Therapeutics Study Status Closed to Follow Up 1077FF: PROMISE 1077FF DAIDS Number 10778 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed Pagination Previous page Prev Page 1 Current page 2 Page 3 Page 4 Next page Next
IMPAACT 2007: Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection DAIDS Number 20734 Research Area Treatment Study Status Concluded
IMPAACT 2000: A Phase I Study of the Safety and Immunogenicity of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID delta M2-2 in RSV-Seronegative Infants and Children DAIDS Number 12016 Research Area Complications & Comorbidities Study Status Concluded
P1115: Very Early Intensive Treatment of Infants Living with HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study DAIDS Number 11954 Research Area Cure and Immunotherapy Study Status Enrolling
P1114: Safety and Immunogenicity of an RSV Vaccine cps2 DAIDS Number 11948 Research Area Complications & Comorbidities Study Status Concluded
P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) Given in Combination with an Individualized Rifampin-Resistant Tuberculosis (RR-TB) Therapy in Infants, Children and Adolescents with RR-TB Disease, Living with or without HIV DAIDS Number 11884 Research Area Tuberculosis Study Status Closed to Accrual
P1104s: Longitudinal Developmental and Neuropsychological Assessments of HIV-Infected Participants of P1060 and HIV-Uninfected Controls DAIDS Number 11878 Research Area Brain and Mental Health Study Status Participants Off Study and Primary Analysis Completed
P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics
P1084s: Maternal Infant TDF Toxicity Safety DAIDS Number 10790 Research Area Therapeutics Study Status Closed to Follow Up
1077FF: PROMISE 1077FF DAIDS Number 10778 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
